Tertomotide

DRACPC ID  DRACPC0010

Active Ingredients   Tertomotide

Description  A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.

Synonyms  GV 1001; GV-1001; GV1001; PrimoVax; Human Telomerase Reverse Transcriptase (EC 2.7.7.49)-(611-626)-Peptide (Telomerase Catalytic Subunit Fragment); Tertomotide

Type  Biotech

Disease  Non-small Cell Lung Cancer, Leukemia, Pancreatic Cancer

Classification

  

Peptide and derivative Vaccine 

Structure Information


Molecular Formula  C85H146N26O21

Molecular Weight  1868.2

Active Sequence  EARPALLTSRLRFIPK

Sequence Length  16

Modification  None

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-6-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid

InChI  InChI=1S/C85H146N26O21/c1-12-47(8)65(81(130)111-38-22-30-63(111)78(127)102-56(82(131)132)25-16-17-33-86)108-75(124)60(42-51-23-14-13-15-24-51)106-71(120)53(26-18-34-94-83(88)89)99-72(121)58(40-45(4)5)104-70(119)54(27-19-35-95-84(90)91)100-76(125)61(43-112)107-79(128)66(50(11)113)109-74(123)59(41-46(6)7)105-73(122)57(39-44(2)3)103-68(117)49(10)98-77(126)62-29-21-37-110(62)80(129)55(28-20-36-96-85(92)93)101-67(116)48(9)97-69(118)52(87)31-32-64(114)115/h13-15,23-24,44-50,52-63,65-66,112-113H,12,16-22,25-43,86-87H2,1-11H3,(H,97,118)(H,98,126)(H,99,121)(H,100,125)(H,101,116)(H,102,127)(H,103,117)(H,104,119)(H,105,122)(H,106,120)(H,107,128)(H,108,124)(H,109,123)(H,114,115)(H,131,132)(H4,88,89,94)(H4,90,91,95)(H4,92,93,96)

InChI_Key WZJRQXZSYQYFJV-UHFFFAOYSA-N

SMILES  CCC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C1CCCN1C(C(NC(C(NC(C(N)CCC(O)=O)=O)C)=O)CCC/N=C(N)/N)=O)=O)C)=O)CC(C)C)=O)CC(C)C)=O)C(O)C)=O)CO)=O)CCC/N=C(N)\N)=O)CC(C)C)=O)CCC/N=C(N)\N)=O)CC2=CC=CC=C2)=O)C(N3CCCC3C(NC(C(O)=O)CCCCN)=O)=O)C

External Codes


PubChem CID  56843375

DrugBank Accession Number  DB12747

NCI Thesaurus Code  C62756  

UNII  55R7RG342O   GSRS

CAS  915019-08-8



Drug approval


Drug indication
    Investigated for use/treatment in Non-small Cell Lung Cancer, Leukemia, Pancreatic Cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT02854072 A Prospective, Randomized, Open-label, Multicenter, Parallel Design, Phase III Study to Assess the Efficacy and Safety of GV1001 Concurrent With Gemcitabine/Capecitabine Versus Gemcitabine/Capecitabine Alone in Treating Locally Advanced and Metastatic Pancreatic Cancer Patients Pancreatic Cancer Phase 3 Treatment
NCT00444782 "Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma. Carcinoma, Hepatocellular Phase 2 Treatment
NCT01247623 Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma Malignant Melanoma Phase 1/2 Treatment
NCT04032067 A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) Benign Prostatic Hyperplasia (BPH) Phase 3 Treatment
NCT03184467 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients Alzheimer Disease Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.